163 related articles for article (PubMed ID: 34254872)
1. Solute carrier transporter superfamily member SLC16A1 is a potential prognostic biomarker and associated with immune infiltration in skin cutaneous melanoma.
Xie J; Zhu Z; Cao Y; Ruan S; Wang M; Shi J
Channels (Austin); 2021 Dec; 15(1):483-495. PubMed ID: 34254872
[TBL] [Abstract][Full Text] [Related]
2. Solute carrier family 16 member 1 as a potential prognostic factor for pancreatic ductal adenocarcinoma and its influence on tumor immunity.
Wang M; Liu L; Li X; Jiang W; Xiao J; Hao Q; Wang J; Reddy AV; Talbot A; Ikuta S; Tian D; Ren L
J Gastrointest Oncol; 2024 Apr; 15(2):730-746. PubMed ID: 38756638
[TBL] [Abstract][Full Text] [Related]
3. Database mining analysis revealed the role of the putative H
Xie J; Ruan S; Zhu Z; Wang M; Cao Y; Ou M; Yu P; Shi J
Channels (Austin); 2021 Dec; 15(1):496-506. PubMed ID: 34334114
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of lactate transporter SLC16A1 and SLC16A3 as oncoimmunological biomarkers associating tumor metabolism and immune evasion in glioma.
Zhu T; Ge X; Gong S; Guo S; Tao Q; Guo J; Ma R
Cancer Innov; 2022 Oct; 1(3):229-239. PubMed ID: 38089757
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA SLC16A1-AS1: its multiple tumorigenesis features and regulatory role in cell cycle in oral squamous cell carcinoma.
Feng H; Zhang X; Lai W; Wang J
Cell Cycle; 2020 Jul; 19(13):1641-1653. PubMed ID: 32450050
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of pan-cancer reveals the potential of SLC16A1 as a prognostic and immunological biomarker.
Chen L; Li Y; Deng X
Medicine (Baltimore); 2023 Mar; 102(11):e33242. PubMed ID: 36930112
[TBL] [Abstract][Full Text] [Related]
7. Identification of immune-related genes with prognostic significance in the microenvironment of cutaneous melanoma.
Qu Y; Zhang S; Zhang Y; Feng X; Wang F
Virchows Arch; 2021 May; 478(5):943-959. PubMed ID: 33179141
[TBL] [Abstract][Full Text] [Related]
8. High Expression of SLC16A1 as a Biomarker to Predict Poor Prognosis of Urological Cancers.
Zhang L; Song ZS; Wang ZS; Guo YL; Xu CG; Shen H
Front Oncol; 2021; 11():706883. PubMed ID: 34631536
[TBL] [Abstract][Full Text] [Related]
9. Interaction of atorvastatin with the human glial transporter SLC16A1.
Sasaki S; Futagi Y; Ideno M; Kobayashi M; Narumi K; Furugen A; Iseki K
Eur J Pharmacol; 2016 Oct; 788():248-254. PubMed ID: 27341998
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
[TBL] [Abstract][Full Text] [Related]
11. The Pivotal Function of SLC16A1 and SLC16A1-AS1 in Cancer Progress: Molecular Pathogenesis and Prognosis.
Zhou Y; Tan F; Wang Z; Zhou G; Yuan C
Mini Rev Med Chem; 2024 Apr; ():. PubMed ID: 38616756
[TBL] [Abstract][Full Text] [Related]
12. SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer.
Sun T; Bi F; Liu Z; Yang Q
Aging (Albany NY); 2020 Jul; 12(13):13281-13296. PubMed ID: 32647070
[TBL] [Abstract][Full Text] [Related]
13. miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1.
Li KK; Pang JC; Ching AK; Wong CK; Kong X; Wang Y; Zhou L; Chen Z; Ng HK
Hum Pathol; 2009 Sep; 40(9):1234-43. PubMed ID: 19427019
[TBL] [Abstract][Full Text] [Related]
14. L Antigen Family Member 3 Serves as a Prognostic Biomarker for the Clinical Outcome and Immune Infiltration in Skin Cutaneous Melanoma.
Song J; Jin C; Chen E; Dong X; Zhu L
Biomed Res Int; 2021; 2021():6648182. PubMed ID: 33829062
[TBL] [Abstract][Full Text] [Related]
15. lncRNA SLC16A1-AS1 as a novel prognostic biomarker in non-small cell lung cancer.
Liu HY; Lu SR; Guo ZH; Zhang ZS; Ye X; Du Q; Li H; Wu Q; Yu B; Zhai Q; Liu JL
J Investig Med; 2020 Jan; 68(1):52-59. PubMed ID: 31371390
[TBL] [Abstract][Full Text] [Related]
16. The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature.
Zhou S; Sun Y; Chen T; Wang J; He J; Lyu J; Shen Y; Chen X; Yang R
Front Cell Dev Biol; 2021; 9():739594. PubMed ID: 34660598
[TBL] [Abstract][Full Text] [Related]
17. Identification of CXCL13 as an Immune-Related Biomarker Associated with Tumorigenesis and Prognosis in Cutaneous Melanoma Patients.
Si Z; Hu H
Med Sci Monit; 2021 Jul; 27():e932052. PubMed ID: 34247183
[TBL] [Abstract][Full Text] [Related]
18. A novel immune-related genes prognosis biomarker for melanoma: associated with tumor microenvironment.
Huang R; Mao M; Lu Y; Yu Q; Liao L
Aging (Albany NY); 2020 Apr; 12(8):6966-6980. PubMed ID: 32310824
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of cutaneous melanoma.
Yang S; Liu T; Nan H; Wang Y; Chen H; Zhang X; Zhang Y; Shen B; Qian P; Xu S; Sui J; Liang G
J Cell Physiol; 2020 Feb; 235(2):1025-1035. PubMed ID: 31240705
[TBL] [Abstract][Full Text] [Related]
20. Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma.
Hu B; Wei Q; Zhou C; Ju M; Wang L; Chen L; Li Z; Wei M; He M; Zhao L
Int Immunopharmacol; 2020 Dec; 89(Pt A):107162. PubMed ID: 33168410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
